Aptinyx up 8% premarket on encouraging NYX-458 data in Parkinson’s

Aptinyx up 8% premarket on encouraging NYX-458 data in Parkinson’s
In a primate model of Parkinson's disease (PD), administration of NYX-458, an NMDA receptor modulator, reversed cognitive deficits in a "rapid, robust and enduring" manner. The company says the ... read more
Source: Bing NewsPublished on 2020-01-30